Back to Search
Start Over
Aspirin Intake and Survival After Breast Cancer
- Source :
- Journal of Clinical Oncology. 28:1467-1472
- Publication Year :
- 2010
- Publisher :
- American Society of Clinical Oncology (ASCO), 2010.
-
Abstract
- Purpose Animal and in vitro studies suggest that aspirin may inhibit breast cancer metastasis. We studied whether aspirin use among women with breast cancer decreased their risk of death from breast cancer. Methods This was a prospective observational study based on responses from 4,164 female registered nurses in the Nurses' Health Study who were diagnosed with stages I, II, or III breast cancer between 1976 and 2002 and were observed until death or June 2006, whichever came first. The main outcome was breast cancer mortality risk according to number of days per week of aspirin use (0, 1, 2 to 5, or 6 to 7 days) first assessed at least 12 months after diagnosis and updated. Results There were 341 breast cancer deaths. Aspirin use was associated with a decreased risk of breast cancer death. The adjusted relative risks (RRs) for 1, 2 to 5, and 6 to 7 days of aspirin use per week compared with no use were 1.07 (95% CI, 0.70 to 1.63), 0.29 (95% CI, 0.16 to 0.52), and 0.36 (95% CI, 0.24 to 0.54), respectively (test for linear trend, P < .001). This association did not differ appreciably by stage, menopausal status, body mass index, or estrogen receptor status. Results were similar for distant recurrence. The adjusted RRs were 0.91 (95% CI, 0.62 to 1.33), 0.40 (95% CI, 0.24 to 0.65), and 0.57 (95% CI, 0.39 to 0.82; test for trend, P = .03) for 1, 2 to 5, and 6 to 7 days of aspirin use, respectively. Conclusion Among women living at least 1 year after a breast cancer diagnosis, aspirin use was associated with a decreased risk of distant recurrence and breast cancer death.
- Subjects :
- Adult
Risk
Cancer Research
medicine.medical_specialty
Breast Neoplasms
Breast cancer
Internal medicine
Anticarcinogenic Agents
Humans
Medicine
Prospective Studies
Prospective cohort study
Estrogen Receptor Status
Survival analysis
Aspirin
business.industry
Anti-Inflammatory Agents, Non-Steroidal
Cancer
Middle Aged
medicine.disease
Survival Analysis
Surgery
Oncology
Relative risk
Female
Breast disease
business
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 28
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi.dedup.....1778723dd7ee72cf56645df7906f6ebb
- Full Text :
- https://doi.org/10.1200/jco.2009.22.7918